Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2022
Programm
Poster
Personen
Suche
DE
Alle Personen
Messoud Ashina
Sortiert nach Typ
Datum
Vorsitz
10.12.2022
09:45
–
10:45
Plenary and EHF session
The involvement of PACAP in migraine pathogenesis
Strauss 2-3
Invited speaker
10.12.2022
10:15
–
10:45
20 Min.
10 Min.
Invited lecture
The role of PACAP in migraine: Insights for clinical studies
Vortrag
07.12.2022
12:15
–
12:16
1 Min.
0 Min.
Waiting for On Demand
Reducing The Load Of Migraine Burden: The Burden Beyond Pain
09.12.2022
16:15
–
16:20
3 Min.
2 Min.
ePoster
P266
Interim Analysis on the Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: The Observational PEARL Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:35
–
16:40
3 Min.
2 Min.
ePoster
P270
Past Preventive Migraine Treatment in Patients Initiating Fremanezumab in Clinical Practice: Interim Data from the PEARL Study
CGRP inhibitors in the clinic, Migraine
Weitere Beteiligungen
07.12.2022
14:05
–
14:15
8 Min.
2 Min.
Abstract lecture
A3
Second messenger signaling bypasses blockade of the calcitonin gene-related peptide (CGRP) receptor to provoke migraine attacks in humans
Basic science, animal models in headache research, Migraine
08.12.2022
13:45
–
13:55
8 Min.
2 Min.
Abstract lecture
A13
One-quarter of individuals with weekly headache have never consulted a medical doctor: A Danish nationwide cross-sectional survey
Epidemiology, Guidelines in headache
08.12.2022
16:00
–
16:05
3 Min.
2 Min.
ePoster
P38
Characterization of adult patients with status migrainosus in a tertiary hospital in Colombia, 2019-2021
Epidemiology, Migraine
08.12.2022
16:10
–
16:15
3 Min.
2 Min.
ePoster
P40
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine
Migraine
08.12.2022
16:35
–
16:40
3 Min.
2 Min.
ePoster
P20
Cluster Headache – The Worst Possible Pain on YouTube
Cluster headache
08.12.2022
16:45
–
16:50
3 Min.
2 Min.
ePoster
P91
Glibenclamide posttreatment does not inhibit levcromakalim induced headache: A randomized clinical trial
Migraine, Neuropeptides, channels in headache
09.12.2022
15:30
–
15:35
3 Min.
2 Min.
ePoster
P137a
Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study
Migraine
09.12.2022
15:30
–
15:35
3 Min.
2 Min.
ePoster
P242
Prevalence of neck pain in migraine: A systematic review and meta-analysis
Epidemiology, Migraine
09.12.2022
15:35
–
15:40
3 Min.
2 Min.
ePoster
P103
Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Migraine
09.12.2022
15:45
–
15:50
3 Min.
2 Min.
ePoster
P141
Safety and tolerability of atogepant: a post hoc analysis of pooled data from four clinical trials
Migraine
09.12.2022
16:05
–
16:10
3 Min.
2 Min.
ePoster
P250
Barriers and gaps in headache education: a national cross-sectional survey of neurology residents in Denmark
Epidemiology, Guidelines in headache
09.12.2022
16:15
–
16:20
3 Min.
2 Min.
ePoster
P129
Atogepant for the Preventive Treatment of Chronic Migraine in Europe: Results From the PROGRESS Study
Migraine
09.12.2022
16:15
–
16:20
3 Min.
2 Min.
ePoster
P111
Eptinezumab for Migraine Prevention in Patients with 2-4 Prior Treatment Failures: DELIVER Subpopulation Analysis
Migraine
09.12.2022
16:15
–
16:20
3 Min.
2 Min.
ePoster
P266
Interim Analysis on the Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: The Observational PEARL Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:20
–
16:25
3 Min.
2 Min.
ePoster
P112
Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With 2–4 Prior Preventive Treatment Failures
Migraine
09.12.2022
16:35
–
16:40
3 Min.
2 Min.
ePoster
P116
Adenosine causes short-lasting vasodilation and headache, but not migraine attacks in migraine patients: A randomized clinical trial
Headache, hormones and dietary, Migraine
09.12.2022
16:35
–
16:40
3 Min.
2 Min.
ePoster
P270
Past Preventive Migraine Treatment in Patients Initiating Fremanezumab in Clinical Practice: Interim Data from the PEARL Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:40
–
16:45
3 Min.
2 Min.
ePoster
P117
Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
Migraine
10.12.2022
08:10
–
08:20
8 Min.
2 Min.
Abstract lecture
A37
Arterial responses to infusion of glucagon-like peptide-1 in humans: A randomized trial study
Migraine, Neuropeptides, channels in headache
v1.20.0
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz